On October 31, Professor Li Liangping, Chairman and Founder of T-Cell Immune (Guangzhou) Technology Co., Ltd., and his team visited Shenzhen Cell Valley for exchange. Wang Jianxun, Chief Scientist of Shenzhen Cell Valley; Tang Xiaomeng, Deputy General Manager; Sun Rui, Head of Marketing; and Wu Xiaosheng, Sales Supervisor, extended a warm welcome and held symposium discussions to jointly explore cooperation directions and specific matters.

First, led by Head of Marketing Sun Rui, the T-Cell Immune team toured Shenzhen Cell Valley's smart exhibition hall, GMP-grade production workshops, and R&D laboratories, gaining an initial understanding of Shenzhen Cell Valley's development history, strategic layout, and comprehensive production and R&D pipelines.

During the symposium, Head of Marketing Sun Rui provided the T-Cell Immune team with a detailed introduction to the company's products and services, its core technology—the advantages of retroviral vectors—cooperation cases, and comprehensive corporate strength. Subsequently, Professor Li Liangping and Professor Wang Jianxun engaged in in-depth exchanges on the current development status of cellular immunotherapy, recent research achievements, TCR-T therapy, and the industrial application of retroviral vectors. Both parties reached a high degree of consensus on the advantages of retroviral vectors, including large packaging capacity and low industrialization costs. They plan to switch the underlying technology of T-Cell Immune's existing TCR-T R&D pipelines to retroviral vectors and engage in comprehensive cooperation in IIT clinical research and new drug applications, deepening the research and development of TCR-T cell therapy and jointly advancing progress and development in the cell and gene therapy field.

Professor Li Liangping highly recognized Shenzhen Cell Valley's technical team and strategic layout. He noted that Shenzhen Cell Valley possesses one of the first R&D and production teams in China to master industrial-grade retroviral vector technology (the PackRV-SS system), and that retroviral vectors, compared with other vectors, offer advantages such as high transfection efficiency and stable expression. He expressed the hope that Shenzhen Cell Valley's core technology—efficient and stable retroviral vectors—would help elevate TCR-T research and clinical application to a new level.

This exchange visit laid a solid foundation for both parties to jointly advance the research and development of TCR-T cell therapy and make positive contributions to truly benefiting cancer patients.

About T-Cell Immune (Guangzhou) Technology Co., Ltd.

T-Cell Immune (Guangzhou) Technology Co., Ltd. focuses on the R&D, production, and services of precision tumor T-cell immunotherapy diagnostic and therapeutic products with significant application prospects, such as TCR-T cell anti-cancer immunotherapy. The company's founder and chairman, Professor Li Liangping, serves as Director of the Clinical Oncology Research Institute at the First Clinical Medical College of Jinan University. The company's core team members all have years of overseas study, biopharmaceutical R&D experience, or long-term pharmaceutical enterprise production and operation management experience. The company possesses a tumor immune cell therapy technology platform, a single-cell sequencing technology and synthetic biology platform, an experimental animal and biocomputing platform, and tumor TIL/organoid culture technology. The company has core R&D laboratories and T-cell laboratories in the South China New Materials Innovation Park in Guangzhou High-tech Development Zone, and has built a 1,000-square-meter GMP cell laboratory and production and testing workshops. The company's first TCR-T product has achieved phased results, capable of targeting various solid tumors including gastric cancer, lung cancer, and breast cancer, with anti-cancer activity higher than similar foreign products; this product is currently undergoing IIT clinical research on cancer patients at a renowned tertiary hospital in Guangzhou.

T-Cell Immune (Guangzhou) Technology Co., Ltd. is committed to providing personalized precision tumor immunotherapy treatment plans for every cancer patient and aims to become a leader in the precision tumor T-cell immunotherapy diagnostic and therapeutic market.